JRF-103

N/A

Report date: 2026/04/30 20:00:20
NME

Base Information

Drug NameJRF-103
Drug Alias NameJRF103JRF-103
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEpidermal growth factor receptor erbB1 inhibitorsReceptor protein-tyrosine kinase erbB-2 inhibitorsReceptor protein-tyrosine kinase erbB-4 inhibitors
TargetsReceptor protein-tyrosine kinase erbB-4Receptor protein-tyrosine kinase erbB-2Epidermal growth factor receptor erbB1
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShenzhen Jinrui Foundation Biotechnology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShenzhen Jinrui Foundation Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A